Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021

Abstract

Evidence on COVID-19 vaccine efficacy/effectiveness (VE) in preventing asymptomatic SARS-CoV-2 infections is needed to guide public health recommendations for vaccinated people. We report interim results of a living systematic review. We identified a total of 30 studies that investigated VE against symptomatic and/or asymptomatic infection. In fully vaccinated individuals, VE against symptomatic and asymptomatic infections was 80–90% in nearly all studies. Fully vaccinated persons are less likely to become infected and contribute to transmission.

Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection with the Delta (B.1.617.2) variant: second interim results of a living systematic review and meta-analysis, 1 January to 25 August 2021

“…Concerns were raised about how well the currently available vaccines protect against this variant. Since January 2021, the Robert Koch Institute (RKI), in collaboration with the National Immunisation Technical Advisory Groups (NITAGs) network coordinated by the European Centre for Disease Prevention and Control (ECDC) is performing a living systematic review on the efficacy, effectiveness and safety of coronavirus disease (COVID-19) vaccines authorised in the European Union (EU) (PROSPERO registration: CRD42020208935) [ 2 ]. Here we present results on the effectiveness and the duration of protection provided by the EU-licensed COVID-19 vaccines in respect to the Delta variant.…”

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus

“…For MVA vectors to advance further into clinical application, there is the need to use them in a more widely distributed human disease. With the SARS-CoV-2/COVID-19 pandemic affecting the world population and, to fight the disease, many different vaccine strategies have been developed, and several of these vaccines have shown high efficacy in humans [ 54 ]. One type of vaccine candidate is based on recombinant MVA, which has shown good immunogenicity profiles and high efficacy against SARS-CoV-2 in preclinical trials [ 55 , 56 , 57 , 58 , 59 ], supporting further development in clinical trials.…”

A renewable resource model of health decision-making: insights to improve health marketing

“…However, perhaps the greatest impact on closing the output tap of the reservoir is the choice to get vaccinated. Both the new mRNA and more traditional vaccines have shown excellent results in their ability to elicit the production of antibodies to the virus, with vaccinated people being less likely to become infected, and if they do, less likely to transmit the virus (e.g., Harder et al, 2021 ). Understandably, the longevity of protection afforded by these vaccines is still under study, as are their long-term side effects.…”